Clinical Trials / Research Studies
Lymphoma Hodgkin New Diagnosis

Hodgkin New Diagnosis

AHOD2131: A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab

  • Ages: 5 Years to 60 Years

This phase III trial compares the effect of adding immunotherapy (brentuximab vedotin and nivolumab) to standard treatment (chemotherapy with or without radiation) to the standard treatment (chemotherapy with or without radiation) alone in improving survival in patients with stage I and II classical ...More

Immunotherapy (Nivolumab or Brentuximab Vedotin) Plus Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage III-IV Classic Hodgkin Lymphoma

  • Ages: 12 Years and older

This randomized phase III trial compares immunotherapy drugs (nivolumab or brentuximab vedotin) when given with combination chemotherapy in treating patients with newly diagnosed stage III or IV classic Hodgkin lymphoma. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body' ...More

PEPN22P1: A Study to Measure How a New Method for Dosing Vincristine in Infants and Young Children Compares to the Standard Dosing Method in Older Children

  • Ages: Up to 12 Years

This early phase I trial compares a new method for dosing vincristine in infants and young children to the standard dosing method based on body size in older children. Chemotherapy drugs, such as vincristine, work in different ways to stop the growth of cancer cells, either by killing the cells, by ...More

Safety and Efficacy of Pembrolizumab (MK-3475) in Children and Young Adults With Classical Hodgkin Lymphoma (MK-3475-667/KEYNOTE-667)

  • Ages: 3 Years to 25 Years

This study will examine the safety and efficacy of pembrolizumab (MK-3475) in combination with chemotherapy in children and young adults with newly diagnosed classical Hodgkin Lymphoma (cHL) who are slow early responders (SERs) to frontline chemotherapy. MK-3475-667: An Open-label, Uncontrolled, Mul ...More

Contact Us

Contact us.

To learn more about available lymphoma clinical trials, contact us at cancer@cchmc.org or 513-636-2799.